Perrigo Co PLC

Most Recent

  • uploads///MYL TEVA strategy
    Miscellaneous

    What Are the Conditions of the Mylan-Teva Deal?

    Mylan said it’s pessimistic that the deal will clear antitrust. Mylan is seeking approval for a generic version of TEVA’s Copaxone, the company’s biggest drug.

    By Brent Nyitray, CFA, MBA
  • uploads///Select Generic Pharma Companies Sales by Geo
    Healthcare

    What Are Biosimilars and Why Do They Benefit Generic Pharma?

    BUTCHER: Going back to what you said about generics being a cheaper alternative, why are they cheaper? DUFFY: The barriers to generic markets are usually a lot lower. If we look at the United States, back in 1984 they passed the Hatch-Waxman Act and essentially what this did was allow for an expedited approval process […]

    By VanEck
  • uploads///pe
    Company & Industry Overviews

    Is Valeant a Good Bet on a Price-to-Earnings Basis?

    On August 11, 2016, Valeant Pharmaceuticals (VRX) was trading at a forward PE (price-to-earnings) multiple of ~3.0x.

    By Jillian Dabney
  • uploads///revenue ee
    Earnings Report

    How Did Valeant Fare in 2Q16?

    Valeant Pharmaceuticals (VRX) announced earnings for 2Q16 on August 9, 2016.

    By Jillian Dabney
  • uploads///MYL TEVA spread
    Miscellaneous

    The Mylan–Teva Deal: Arbitrage Spread Analysis

    The key to the Mylan–Teva merger is understanding the process that companies go through when approached with an unsolicited proposal.

    By Brent Nyitray, CFA, MBA
  • uploads///s
    Company & Industry Overviews

    Citron Research Tweet Pulled NVIDIA Prices Lower on December 28

    The S&P 500 Information Technology sector fell 0.87% on December 28. NVIDIA (NVDA) and First Solar (FSLR) were the top losers.

    By Val Kensington
  • uploads///revenue margin projections
    Company & Industry Overviews

    Projected Revenue for Valeant in 2017

    Valeant Pharmaceuticals (VRX) has been keeping an eye on the progress of its dermatology and gastrointestinal portfolio.

    By Jillian Dabney
  • uploads///PRGO
    Consumer

    Must-know: Davidson Kempner exits position in Perrigo

    Perrigo acquired Irish biotech company Elan last year for $8.6 billion.

    By Samantha Nielson
  • uploads///thermometer _
    Earnings Report

    Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance

    Eli Lilly and Co. reported revenues of ~$5.7 billion for 1Q18 today, reflecting 9% growth from 1Q17.

    By Mike Benson
  • uploads///AAPLQ
    Tech & Comm Services

    Davidson Kempner Capital buys a new 4Q13 stake in Apple

    Davidson Kempner added a new position in Apple Inc. (AAPL) that accounted for 2.19% of the fund’s 4Q portfolio. Apple found favor with hedge funds last quarter.

    By Samantha Nielson
  • uploads///ANR
    Company & Industry Overviews

    What Do Analysts Recommend for Valeant after Recent Happenings

    The consensus 12-month target price for Valeant Pharmaceuticals is $36, which translates to a ~77.3% return potential compared to Valeant’s closing price of $20.3 on November 2, 2016.

    By Jillian Dabney
  • uploads///Chart  EPS
    Miscellaneous

    Understanding Allergan’s Valuation after the 1Q17 Results

    On May 10, 2017, Allergan (AGN) was trading at a forward PE multiple of ~14.1x, as compared to the industry average of 11.9x.

    By Mike Benson
  • uploads///PRGO MYL Spread
    Miscellaneous

    What’s the Spread in the Perrigo–Mylan transaction?

    In the Perrigo–Mylan situation, Mylan sent a bear hug letter to Perrigo to express its interest in it. Perrigo rejected that approach, and so Mylan went and filed a formal offer.

    By Brent Nyitray, CFA, MBA
  • uploads///Three share prices
    Earnings Report

    The Many Reasons Mylan Is So Keen to Acquire Perrigo

    On April 21, 2015, Teva (TEVA) launched a proposal to acquire Mylan for $82 a share in a 50% cash, 50% stock deal worth $43 billion. Mylan rejected the offer.

    By Nicole Sario
  • uploads///Geographic exposure
    Company & Industry Overviews

    Central Nervous System Is Key to Teva’s Specialty Medicines

    Revenues for Teva’s (TEVA) Specialty Medicines segment grew by 2.1% to $8,560 million in 2014, from $8,388 million in 2013.

    By Nicole Sario
  • uploads///ETFs
    Company & Industry Overviews

    ETFs Capitalize on the Generic Industry’s Growth

    ETFs are the investment funds—like index funds and mutual funds—that track an index, a commodity, or a basket of assets. ETFs are publicly traded on an exchange.

    By Nicole Sario
  • uploads///Graph
    Company & Industry Overviews

    Akorn’s Macro-Level Challenges in the Generic Drug Segment

    Although generic drugs only account for 3% of the total healthcare costs in the US, regulators continue to be concerned about rising generic pricing.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Price Erosion Could Impact Perrigo’s Prescription Drug Business

    Perrigo expects its prescription drug business to earn revenues of ~$1 billion in 2016. It estimated an adjusted operating margin of 40%–45% in 2016.

    By Margaret Patrick
  • uploads///MYL TEVA overview
    Miscellaneous

    Teva Pharmaceuticals Makes a Hostile Bid for Mylan

    There has been press speculation that Teva was interested in Mylan, and Mylan actually responded last Friday to this speculation with a press release.

    By Brent Nyitray, CFA, MBA
  • uploads///Part
    Consumer

    David Einhorn Was Right about Apple

    Greenlight Capital (GLRE) exited its position in Apple in the third quarter of 2018.

    By Anuradha Garg
  • uploads///Chart  LLY
    Company & Industry Overviews

    Eli Lilly Stock’s June Performance

    Leading US pharmaceutical company Eli Lilly (LLY) specializes in human pharmaceuticals and animal health.

    By Mike Benson
  • uploads///s
    Company & Industry Overviews

    S&P 500 Closed Higher amid Trump’s News Conference

    After closing flat for the first time in nine years on Tuesday, the S&P 500 was volatile on Wednesday. On January 11, it closed the day at 2,275.32.

    By Val Kensington
  • uploads///Mylan Analyst Estimates Part
    Earnings Report

    The Majority of Brokers Recommend a “Buy” for Mylan

    Mylan is expected to announce its fourth quarter earning for 2015 on February 10, 2016. As of January 22, 2016, Mylan’s market cap stood at $26.1 billion.

    By Peter Neil
  • Consumer

    Why Bridgewater starts new position in Bed, Bath and Beyond

    Bridgewater Associates disclosed a new position in Bed, Bath & Beyond (BBBY). It accounted for 0.11% of the fund’s total portfolio.

    By Patricia Garner
  • uploads///csco
    Tech & Comm Services

    Why Bridgewater Associates decreased its position in Cisco

    Bridgewater Associates decreased its position in Cisco from 0.20% in the 1Q portfolio to 0.09% in the fund’s 2Q portfolio.

    By Patricia Garner
  • Healthcare

    Davidson Kempner Capital buys a new position in LSI in 4Q13

    Davidson Kempner added a new position in LSI Corp. (LSI) that accounted for 1.39% of the fund’s 4Q portfolio.

    By Samantha Nielson
  • uploads///DavidsonQ
    Consumer

    Assessing Davidson Kempner Capital Management’s 4Q13 positions

    Davidson Kempner Capital Management LLC is a hedge fund manager led by president Thomas Kempner, Jr., who joined the firm in 1984. It has about $22 billion in assets under management.

    By Samantha Nielson
  • uploads///Chart
    Company & Industry Overviews

    What Are Pfizer’s Revenue Drivers?

    Pfizer reported revenues of $13.5 billion during the second quarter—4% growth YoY compared to $12.9 million during the second quarter of 2017.

    By Mike Benson
  • uploads///rawpixel  unsplash
    Company & Industry Overviews

    Analyzing Perrigo’s Spin-Off of Its Rx Business

    In this series, we’ll analyze major spin-offs in the healthcare sector by Perrigo (PRGO), Eli Lilly (LLY), Danaher (DHR), and Henry Schein.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    How Eli Lilly’s Business Segments Performed in Q2 2018

    Eli Lilly and Company reports its business revenue under two segments: the Human Pharmaceutical segment and Elanco, the Animal Health segment.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts’ Recommendations for DaVita

    As discussed previously, analysts expect DaVita (DVA) to post revenue of $2.877 billion, adjusted net income of ~$175.97 million, and non-GAAP EPS of ~$0.97 in Q2 2018.

    By Mike Benson
  • uploads///gAINERS
    Company & Industry Overviews

    S&P 500’s Top Gainers: Perrigo and Charles Schwab

    Perrigo, which is an American international manufacturer of private label over-the-counter pharmaceuticals, was the S&P 500’s top gainer on July 17.

    By Val Kensington
  • uploads///Chart
    Company & Industry Overviews

    Sage Therapeutics’ NMDA Receptor–Based Products

    Sage Therapeutics developed SAGE-718, which targets the NMDA Receptor.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    Pfizer’s EC Approval of Xeljanz for Active Psoriatic Arthritis

    Pfizer (PFE) announced in a press release yesterday that the European Commission has approved its marketing authorization application for Xeljanz in combination with methotrexate for active psoriatic arthritis.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s US Specialized Therapeutics Segment

    Allergan’s (AGN) US Specialized Therapeutics segment includes revenue from the US sales of specialized products.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    These Pfizer Products Saw Declining Sales in 4Q17

    A few products in Pfizer’s (PFE) portfolio reported declining sales in 4Q17 following their loss of market share to the competition.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    GlaxoSmithKline Could Witness Modest Rise in Revenues in 2017

    GlaxoSmithKline (GSK) is a leading player in the global respiratory market with a major focus on the asthma and chronic obstructive pulmonary disease (or COPD) segments.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for GlaxoSmithKline in January 2018

    Of the 31 analysts covering GlaxoSmithKline in January 2018, five have recommended a “strong buy,” seven have recommended a “buy,” 15 have recommended a “hold,” three have recommended a “sell,” and only one has recommended a “strong sell.”

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    Pfizer: Revenue Growth Is Expected in 4Q17

    Wall Street analysts expect Pfizer’s (PFE) revenues to increase ~0.7% to $13.72 billion during 4Q17—compared to revenues of $13.63 billion during 4Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Recent Developments for Mylan

    Recent developments reported by Mylan (MYL) include commercial developments as well as product developments. Let’s take a closer look.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Elagolix May Advance the Treatment Paradigm in Women’s Health

    On October 27, 2017, AbbVie (ABBV) announced that the New Drug Application for its investigational drug Elagolix had been granted priority review by the FDA.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Mylan’s Valuation in January 2018

    Mylan (MYL) is a leading pharmaceutical company with over 1,400 generic and specialty pharmaceutical products in its portfolio.

    By Mike Benson
  • uploads///Chart  BS
    Company & Industry Overviews

    Eli Lilly’s Business Segments in 3Q17

    Eli Lilly’s human pharmaceuticals segment contributed ~87% of Eli Lilly’s total revenues in 3Q17.

    By Mike Benson
  • uploads///Chart  Oncology
    Company & Industry Overviews

    Behind Eli Lilly’s Alimta and Other Oncology Products in 3Q17

    In 3Q17, Eli Lilly’s overall revenues from oncology products fell due to lower sales of Alimta, Erbitux, and Portrazza, offset by a rise in Cyramza sales.

    By Mike Benson
  • uploads///Chart  New
    Company & Industry Overviews

    Eli Lilly’s New Pharmaceutical Products in 3Q17

    Eli Lilly’s (LLY) new products include Basaglar, Cyramza, Jardiance, Lartruvo, Olumiant, Taltz, and Trulicity.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Merck’s 3Q17 Revenues Could Rise

    Analysts expect Merck’s (MRK) revenues for 3Q17 to be around $10,546 million, nearly a 0.1% increase as compared to the revenues of $10,536 million reported for 3Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Sanofi’s Consumer Healthcare Expected to Be Long-Term Driver

    In 2Q17, Sanofi’s (SNY) Consumer Healthcare business reported revenues of 1.2 billion euros, which is a 42.5% YoY rise on a CER basis and a YoY fall of 0.10% on a CER and CS basis.

    By Margaret Patrick
  • uploads///graph_
    Company & Industry Overviews

    Why Mylan Lowered Its Revenue Guidance for 2017

    In its 2Q17 earnings conference call, Mylan (MYL) reduced its revenue guidance for 2017 from a range of $12.25 billion–$13.75 billion to a range of $11.5 billion–$12.5 billion.

    By Margaret Patrick
  • uploads///Chart  Keytruda
    Company & Industry Overviews

    Behind the Latest Developments for Merck’s Keytruda

    Keytruda (pembrolizumab) is a prescription medicine from Merck’s (MRK) immuno-oncology franchise used for the treatment of various tumors.

    By Mike Benson
  • uploads///Chart  Cardio
    Company & Industry Overviews

    Eli Lilly’s Cardiovascular Products in 2Q17

    Eli Lilly and Co.’s (LLY) cardiovascular franchise includes two drugs—Cialis and Effient. These drugs comprise ~15.0% of the company’s total revenues.

    By Mike Benson
  • uploads///Part  ALB
    Company & Industry Overviews

    Albemarle Appointed Laurie Brlas to Board of Directors

    For the week ended June 30, 2017, Albemarle (ALB) rose 0.7% and closed at $105.54.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Dupixent May Be a Major Growth Driver for Regeneron in 2017

    After Dupixent’s commercial launch, Regeneron has been involved in creating awareness for the drug among physicians who have been treating AD patients.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Mylan’s Valuation Compared to Its Peers

    As of January 10, 2017, Mylan (MYL) was trading at a forward PE (price-to-earnings) multiple of ~7.3x, compared to the industry average of 16.3x.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s Valuation Compared to Its Peers

    Allergan’s stock value fell more than 40% over the last 12 months. Analysts estimate that the stock could to return ~39.5% over the next 12 months.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Pfizer Has a Revenue-Boosting Treatment to Help Smokers Quit

    Approved by the FDA on May 11, 2006, Chantix, also known as Champix, is used as an aid to help cigarette smokers quit the habit of smoking.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Strong Brand Positioning Expected to Strengthen Teva’s Position

    Teva Pharmaceutical’s (TEVA) strategy of selectively focusing on certain countries has enabled it to see double-digit organic growth in the growth markets.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Is Teva Positioned to Compete with the Likes of Mylan and Novartis?

    In 2Q16, the generic pharmaceutical industry witnessed YoY (year-over-year) price erosion of around 4% in the US and 5% globally.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva Is Well Positioned for New Trends in the US Generic Market

    Because of its drug portfolio, manufacturing operations, and customer relationships, Teva expects to benefit from new trends in the US generic market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva’s OTC Business Is Playing out to Be a Key Growth Driver

    In addition to its generic pharmaceutical business, Teva Pharmaceutical also has a significant presence in the major categories of the OTC drug business.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Consumer Healthcare Segment Expects Revenue of $2.6 Billion in 2016

    Similar to what it witnessed in 1H16, the company also expects the CHC (Consumer Healthcare) segment’s adjusted operating margins to remain strong in 2H16.

    By Margaret Patrick
  • Company & Industry Overviews

    The American Century Growth Fund Is Holding Its Own in YTD 2016

    Both consumer-focused sectors—discretionary and staples—have been sizable positive contributors to TWCGX.

    By David Ashworth
  • uploads///Graph
    Company & Industry Overviews

    Akorn in 2016: What Are Its Key Risk Factors?

    In addition to industry-specific risks faced by all generic pharmaceutical players, Akorn (AKRX) faces certain company-specific risks.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Akorn’s Robust Research and Development Pipeline: A Growth Driver

    Akorn’s (AKRX) robust research and development pipeline is comprised of branded and generic drugs with a total addressable market value of about $9.2 billion.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    How Did Bristol-Myers Squibb’s Eliquis Perform?

    Bristol-Myers Squibb’s (BMY) cardiovascular segment consists of its key drug Eliquis. This segment contributed nearly 78% of total revenues for 2Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Will Anda Acquisition Improve Access to Teva’s Generic Drugs?

    On August 3, 2016, Teva Pharmaceutical (TEVA) announced that it will acquire Anda, Allergan’s pharmaceutical distributor business, for about $500 million.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva Pharmaceutical: A Successful Bond Financing Program in 2016

    To finance the acquisition of Allergan Generics (AGN), Teva Pharmaceutical (TEVA) successfully completed a global bond offering on July 21, 2016.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Analysts Recommending for Teva Pharmaceutical in 2016?

    Among the 32 analysts surveyed by Bloomberg for Teva Pharmaceutical (TEVA), 74.2% gave it a “buy” rating, and 25.8% gave it a “hold.” No analysts rated it a “sell.”

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Understanding Akorn’s Focus on Inorganic Growth

    Since 2011, Akorn (AKRX) has focused on acquisitions that either expand the company’s core capabilities or increase its geographic market access.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alternate Dosage Forms Are Expected to Drive Akorn’s Growth in 2016

    Akorn’s (AKRX) extensive alternate dosage form portfolio is comprised of topical creams, oral liquids, nasal sprays, injectables, ophthalmics, and otic solutions.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    Perrigo Stock Skyrockets Due to Takeover Talks

    On June 14, Perrigo was the top performer within the Health Care Select Sector SPDR ETF (XLV). It gained 9.2% and outperformed the SPDR S&P 500 ETF (SPY).

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Teva Aims to Improve Its Position with Actavis Generics Acquisition

    Teva Pharmaceutical expects to benefit from improved productivity after the completion of the deal with Actavis Generics.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    What Caused Alexion Pharmaceuticals’ Fall?

    Alexion Pharmaceuticals was the second-worst performing stock within the Health Care Select Sector SPDR ETF (XLV), falling by 10.9% on June 7, 2016.

    By Peter Neil
  • Company & Industry Overviews

    Why a Good Start to 2016 Has Turned Average for TWCGX

    As of May 27, 2016, the American Century Growth Fund Investor Class (TWCGX) had posted a rise of 0.2% YTD (year-to-date).

    By David Ashworth
  • uploads///Portfolio Breakdown of the TWCGX
    Company & Industry Overviews

    A Look at Portfolio Changes in TWCGX

    The American Century Growth Fund Investor Class (TWCGX) invests in companies that its managers believe will increase in value over time.

    By David Ashworth
  • uploads///Graph
    Company & Industry Overviews

    Branded Consumer Healthcare Business May Impact Perrigo’s Valuations

    The Branded Consumer Healthcare (or BCH) segment, a part of Perrigo’s consumer-facing business, is expected to account for about 25% of the company’s total revenues in 2016.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Consumer Healthcare Should Be a Key Driver of Perrigo’s 2016 Growth

    The Consumer Healthcare (or CHC) segment, a key part of Perrigo’s consumer business, is expected to account for about 45% of the company’s total revenues in 2016.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Market Dynamics Should Strengthen Perrigo’s OTC Business in 2016

    Perrigo (PRGO) is expected to witness an organic growth of 5%–10% in its consumer over-the-counter product revenues in 2016.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Analysts Expect Mylan’s Net Profit Margins to Rise in 2016

    Mylan (MYL) expects improved net profit margins in 2016, mainly due to the operational synergies projected as a result of its acquisition of Meda AB.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Can We Expect for Teva’s Net Profit Margins in 2016?

    Teva Pharmaceutical Industries (TEVA) is expected to boost its net profit margins in 2016.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Can We Expect from Teva’s Respiratory Portfolio in 2016?

    Teva Pharmaceutical Industries (TEVA) has been actively involved in developing and commercializing a breath-actuated dry-powder inhaler.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Mylan Plans to Leverage Its Meda Acquisition

    Mylan (MYL) believes that after the acquisition of Meda, the combined company will have six franchises worth $1 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Is Meda AB a Strategic Fit for Mylan’s Business?

    On February 10, 2016, Mylan (MYL) announced its decision to acquire Meda AB for a consideration of $9.9 billion through a public offer.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    XLV Rose as 52 of Its Holdings Posted Positive Returns

    XLV rose 1.4% on February 22, 2016, as 52 of its holdings posted positive returns. Only four of XLV’s stocks ended in the red.

    By Peter Neil
  • uploads///Graph
    Miscellaneous

    Perrigo Considered Mylan’s Offer to Be Dilutive to EPS

    Perrigo’s management strongly believed that a combination with Mylan would result in at least three years of substantial EPS dilution.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Perrigo Benefits from Omega Pharmaceuticals Acquisition

    In March 2015, Perrigo acquired Omega Pharmaceuticals. adding many leading consumer healthcare brands to its existing portfolio.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Perrigo Leads the Over-the-Counter Store-Branded Products Market

    Perrigo is a market leader in over-the-counter store-branded products. Its leadership position extends to major geographies such as the US, the UK, and Mexico.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Perrigo Adopts Base Plus Plus Plus Strategy for Continued Growth

    The Base Plus Plus Plus business model has been instrumental in Perrigo’s commercial success despite tough competition from peers.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Perrigo’s Diversified Prescription Pharmaceuticals Franchise

    Perrigo offers diversified prescription pharmaceuticals, including generic and specialty prescription pharmaceuticals, in the US and UK.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Perrigo’s Strong Presence in the European-Branded OTC Market

    Post-completion of its March 2015 acquisition of Omega, Perrigo has actively entered the European-branded OTC market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    An Overview of Perrigo’s Business Model

    Perrigo’s business model includes a well-aligned organizational structure of its segments and a strong product portfolio.

    By Margaret Patrick
  • uploads///Article
    Company & Industry Overviews

    Nutritionals: Abbott Laboratories’ Main Segment

    Abbott Laboratories’ (ABT) nutritional products segment includes a broad line of pediatric and adult nutritional products manufactured and marketed worldwide.

    By Mike Benson
  • uploads///Graph
    Miscellaneous

    Teva and Allergan Generics Deal Displays Other Synergies

    Teva projects that the Allergan Generics deal should help Teva realize annualized cost synergies and tax savings of approximately $1.4 billion.

    By Margaret Patrick
  • uploads///Margins
    Earnings Report

    Why Teva’s Generic Medicines Profitability Improved in 1Q15

    Teva’s increased profitability for its generic medicines was partially offset by decreased profitability of its specialty medicines, which were down by 13% in 1Q15 from 1Q14.

    By Nicole Sario
  • uploads///EPS
    Earnings Report

    Mylan Reports 1Q15 Earnings Per Share Growth of 6%

    With the acquisition of Abbott Laboratories’ (ABT) non-US developed markets specialty and branded generics business, Mylan relocated its headquarters to the Netherlands.

    By Nicole Sario
  • uploads///ASPX acquisition
    Earnings Report

    Teva Earnings Preview: Auspex Acquisition to Support Growth

    Acquisition rationale On March 30, 2015, Teva Pharmaceutical Industries (TEVA) announced its agreement to acquire Auspex Pharmaceuticals (ASPX) for $3.2 billion in enterprise value, a 42.4% premium to the company’s closing share price of $70.91 on March 27, 2015. This step will support the company’s near- and mid-term growth. Teva share price moved up a marginal […]

    By Nicole Sario
  • uploads///PRGO_Rx to OTC
    Miscellaneous

    Mylan–Perrigo Merger: Expanding into Over-the-Counter Drugs

    Pharmaceutical company Mylan’s (MYL) intention to acquire Perrigo became public on April 6, 2015. The acquisition would permit Mylan to expand into the over-the-counter drugs segment.

    By Nicole Sario
  • uploads///Combined product portfolio
    Fund Managers

    Magnetar Capital Raises Its Stake in Actavis

    In the fourth quarter, Magnetar increased its exposure to Actavis. It bought 42,107 shares in the pharmaceutical firm. It represents 1.5% of the fund’s 4Q14 portfolio.

    By Santiago Solari
  • uploads///Specialty drug outlook
    Company & Industry Overviews

    What Are Teva’s Long-Term Prospects?

    Teva’s long-term prospects seem bright due to a focused product pipeline in its specialty and generics segments.

    By Nicole Sario
  • uploads///Business Model
    Company & Industry Overviews

    Why Teva’s Business Model Is Progressively Evolving

    Teva intends to target a minimum annual profit of $4.3 billion, or $5 EPS, through 2016. To achieve this, Teva is reorienting its business model.

    By Nicole Sario
  • uploads///Value Chain
    Company & Industry Overviews

    Generics Are Climbing up the Value Chain

    Severe cost pressure can lead to the commoditization of generics. it’s important to adjust the value chain to achieve higher efficiencies, flexibility, and reliability.

    By Nicole Sario
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.